Tanezumab reduces osteoarthritic knee pain: Results of a randomized, double-blind, placebo-controlled phase III trial

Journal of Pain

Volumn 13, Issue 8, 2012, Pages 790-798

  Brown, Mark T ^a   Murphy, Frederick T ^b,c   Radin, David M ^d   Davignon, Isabelle ^a   Smith, Michael D ^a   West, Christine R ^a  

^a PFIZER INC   (United States)

^b Altoona Center for Clinical Research   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Stamford Therapeutics Consortium   (United States)

Author keywords

analgesia; nerve growth factor; osteoarthritis; pain; randomized controlled trial; Tanezumab

Indexed keywords

TANEZUMAB;

ADULT; AGED; ALLODYNIA; ARTHRALGIA; ARTICLE; BURNING SENSATION; CARPAL TUNNEL SYNDROME; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FALLING; FEMALE; HUMAN; HYPERESTHESIA; HYPESTHESIA; JOINT INJURY; KNEE PAIN; LIMB PAIN; MALE; MERALGIA PARESTHETICA; MYALGIA; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84864454394     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2012.05.006     Document Type: Article

References (30)

1. Y.N. Abdiche, D.S. Malashock, and J. Pons Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci 17 2008 1326 1335
2. American College of Rheumatology Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum 43 2000 1905 1915
3. P.A. Barker, and R.A. Murphy The nerve growth factor receptor: A multicomponent system that mediates the actions of the neurotrophin family of proteins Mol Cell Biochem 110 1992 1 15
4. J.M. Bjordal, A. Klovning, A.E. Ljunggren, and L. Slordal Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials Eur J Pain 11 2007 125 138
5. J.M. Bjordal, A.E. Ljunggren, A. Klovning, and L. Slordal Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials BMJ 329 2004 1317
6. M.T. Brown, F.T. Murphy, D.M. Radin, I. Davignon, M.D. Smith, and C.R. West A phase 3 randomized, double-blind, placebo-controlled trial of analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip. Late-breaking abstracts: American College of Rheumatology 2010 Annual Scientific Meeting Arthritis Rheum 62 2010 3837 3845
7. C.F. Dillon, E.K. Rasch, Q. Gu, and R. Hirsch Prevalence of knee osteoarthritis in the United States: Arthritis data from the Third National Health and Nutrition Examination Survey 1991-94 J Rheumatol 33 2006 2271 2279
8. J. Fidelholtz, M. Tark, E. Spierings, G. Wolfram, K. Annis, M.D. Smith, M.T. Brown, and C.R. West A phase 3 placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis [abstract] Arthritis Rheum 63 2011 S427
9. J.M. Frade, and Y.A. Barde Nerve growth factor: Two receptors, multiple functions Bioessays 20 1998 137 145
10. G.A. Hawker Who, when, and why total joint replacement surgery? The patient's perspective Curr Opin Rheumatol 18 2006 526 530
11. F. Hefti, M. Mokhtarani, M. Gray, C. Zhao, and C. Chan RN624 (anti-NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the knee J Pain 7 2006 S45
12. F.F. Hefti, A. Rosenthal, P.A. Walicke, S. Wyatt, G. Vergara, D.L. Shelton, and A.M. Davies Novel class of pain drugs based on antagonism of NGF Trends Pharmacol Sci 27 2006 85 91
13. Hertz S, Fields E: Addendum to the background package for the March 12, 2012, AAC Meeting, regarding the agency adjudication of cases of joint replacements occurring in clinical trials of anti-NGF agents. 2012
14. S.P. Johnsen, H. Larsson, R.E. Tarone, J.K. McLaughlin, B. Norgard, S. Friis, and H.T. Sorensen Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study Arch Intern Med 165 2005 978 984
15. N. Katz The impact of pain management on quality of life J Pain Symptom Manage 24 2002 S38 S47
16. J.H. Kellgren, and J.S. Lawrence Radiological assessment of osteo-arthrosis Ann Rheum Dis 16 1957 494 502
17. N. Lane, L. Webster, L. Shiao-Ping, M. Gray, F. Hefti, and P. Walicke RN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: A phase I study Arthritis Rheum 52 2005 S461
18. N.E. Lane, T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, M.D. Smith, and M.T. Brown Tanezumab for the treatment of pain from osteoarthritis of the knee N Engl J Med 363 2010 1521 1531
19. P. Mantyh, L. Tive, and D. Shelton Tanezumab, a humanized anti-nerve growth factor antibody for the treatment of pain J Pain 10 2009 S44
20. S.B. McMahon NGF as a mediator of inflammatory pain Philos Trans R Soc Lond B Biol Sci 351 1996 431 440
21. G.D. Nicol, and M.R. Vasko Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv 7 2007 26 41
22. J.C. Petruska, and L.M. Mendell The many functions of nerve growth factor: Multiple actions on nociceptors Neurosci Lett 361 2004 168 171
23. Pfizer: TANEZUMAB ARTHRITIS ADVISORY COMMITTEE BRIEFING DOCUMENT. February 8, 2012. URL: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm286556. htm. Accessed April 4, 2012.
24. Rappaport BA: US Food and Drug Administration Center for Drug Evaluation and Research: Background materials. February 13, 2012. URL: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/ucm295201.htm. Accessed April 4, 2012.
25. T.J. Schnitzer, N.E. Lane, C. Birbara, M.D. Smith, S.L. Simpson, and M.T. Brown Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain Osteoarthritis Cartilage 19 2011 639 646
26. S.D. Skaper The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors CNS Neurol Disord Drug Targets 7 2008 46 62
27. A. Whelton Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics Am J Ther 7 2000 63 74
28. C.J. Woolf, B. Safieh-Garabedian, Q.P. Ma, P. Crilly, and J. Winter Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity Neuroscience 62 1994 327 331
29. U. Yazici, E.F. Ekman, H.S. Greenberg, M.D. Smith, M.T. Brown, C.R. West, and K.M. Verburg Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354) [abstract] Arthritis Rheum 63 2011 S326
30. W. Zhang, R.W. Moskowitz, G. Nuki, S. Abramson, R.D. Altman, N. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, and P. Tugwell OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines Osteoarthritis Cartilage 16 2008 137 162